Recently, the National Medical Insurance Administration issued the "Reply of the National Medical Insurance Administration to Suggestion No. 2090 of the Second Session of the Fourteenth National People's Congress" (hereinafter referred to as the "Reply"). In the "Reply", the National Medical Insurance Administration explained the next steps for the centralized procurement of consumables and the implementation of innovative medical devices.

In particular, the next steps for local centralized procurement were explained. The "Reply" pointed out that centralized procurement is still in the stage of reform and overcoming difficulties. The National Medical Insurance Administration will further supervise and improve the rules of local centralized procurement, improve the scientificity and standardization of local centralized procurement, and improve the quality and efficiency of procurement. First, expand the scope of the alliance and strengthen national coordination. Encourage local governments to carry out alliance procurement, and upgrade to national alliance procurement if conditions are met. The National Medical Insurance Administration will provide overall guidance, coordinate experts to provide technical support, and improve the ability to standardize work. Second, improve procurement rules and strengthen the scientificity of centralized procurement. It is required that localities fully learn from the experience of the national and other local centralized procurement, conduct in-depth investigations and research, listen to opinions and suggestions from all parties, follow the principle of "one product, one policy", form scientific procurement rules according to product characteristics, and organize procurement in a standardized manner. Third, implement the reform in a refined manner and consolidate the results of the reform. With the continuous expansion of centralized procurement, supervision of all aspects of centralized procurement is also being strengthened.

The above-mentioned "Reply" proposes that the National Medical Insurance Administration will work with relevant departments to establish and improve the incentive and constraint mechanism for medical institutions and selected enterprises to ensure that the selected products are purchased and used first and supplied in sufficient quantities. Medical institutions are required to open up channels for the selected products to enter hospitals and ensure timely entry into hospitals. The "Reply" proposes to strengthen the monitoring and assessment of the implementation of centralized procurement by medical institutions, and regularly report and interview medical institutions with poor implementation. For selected enterprises that have not supplied in time for a long time, measures such as cancellation of the selected qualification, inclusion in the centralized procurement violation list, and dishonesty evaluation will be taken. In the subsequent procurement after the expiration of the agreement, incentives or constraints will be given according to the performance of the contract in the selected ranking, so as to encourage enterprises to fulfill their contracts in good faith and supply with quality and quantity.

In terms of the next step of innovative medical devices, the "Reply" proposes that in terms of the application of innovative domestic medical device products, the National Health Commission has specially arranged a series of medical device product application solution research, application evaluation and demonstration research projects to establish an effective link between the industrial end and the application end. First, based on domestic innovative devices that have obtained registration certificates, conduct solution research on new clinical technologies and new service models in clinical institutions to form replicable solutions, laying a technical foundation for the application demonstration and clinical promotion of domestic innovative devices. Second, select medical institutions in different regions, levels and types across the country to systematically carry out industrial demonstration, clinical application evaluation and demonstration research of domestic innovative products to solve the problem of difficulty in opening and expanding the market for domestic medical devices. Third, explore the establishment of high-end domestic medical device application demonstration and other assessments in the construction of platforms such as the National Clinical Medical Research Center.

It is not difficult to see that in the process of promoting centralized procurement of consumables, local centralized procurement plays an increasingly important role. In addition to national procurement, local centralized procurement has developed from a small-scale pilot in the early stage to a new pattern of parallel city alliances, provincial, inter-provincial alliances and even national alliances.
This year, the National Medical Insurance Administration proposed for the first time that "provincial alliance procurement should further strengthen national coordination, and upgrade to national alliance procurement if conditions are met." Biochemical in vitro diagnostic reagents, tumor markers and other in vitro diagnostic reagents, ultrasonic blades, breast cutting needles, vascular tissue closure ligation clips, coronary cutting balloons, vascular intervention and other centralized procurement have become the national joint procurement projects that the National Medical Insurance Administration focuses on guiding this year.

At the local level, the "filling gaps" and "trying new things" of centralized procurement of consumables are being continuously promoted. On the one hand, some regions have already carried out centralized procurement, but there are still some regions that have not yet carried out centralized procurement, which have become the key promotion targets at the local level. According to the plan, hemostatic materials, patches, in vitro diagnostic reagents and other varieties that have been carried out in many provinces will be included in the scope of centralized procurement through volume-based price linkage and other methods.

In addition, some exploratory new projects are also being carried out one after another. For example, Jiangsu Province launched the volume-based procurement of non-invasive prenatal genetic testing services this year. This is also the first time that this category has been included in the volume-based procurement. After soliciting opinions, Jiangsu raised the highest effective bid price in the centralized procurement, and other parts of the content were also adjusted to make it more in line with the actual situation of the industry. Overall, local centralized procurement is expected to be more complete in terms of rules. At the same time, the situation of "one chess game" of consumables prices across the country has become clearer.

https://mp.weixin.qq.com/